EAN 2023 | Parkinson’s disease: updates in the disease-modifying space

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, discusses the advancements in disease-modifying approaches for Parkinson’s disease (PD). Multiple strategies are being investigated to modify the disease trajectory, including monoclonal antibodies like prasinezumab, therapies for patients with genetic mutations, engineered stem cells, and gene therapies via viral vectors. The varied areas of research mark an exciting time in the disease-modifying space. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.